



OxySure (OXYS) Appoints Dr. Joseph M. Chalil to Strategic Advisory Board

Frisco, Texas, September 30, 2015 -- (Marketwired) -- OxySure Systems, Inc. (OTCQB: OXYS) (OxySure, or the Company), the medical device innovator of life-saving easy-to-use emergency oxygen solutions with its “oxygen from powder” technology and other emergency medical solutions, announced that it has appointed Dr. Joseph M. Chalil, MD, MBA, FACHE, to its Strategic Advisory Board.

Dr. Chalil (42) is a Physician and Executive at Boehringer Ingelheim, the world's largest privately held pharmaceutical company. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.

In addition to his responsibilities at Boehringer Ingelheim, Dr. Chalil is the Chairman of Global Clinical Research and Trial Network of the American Association of Physicians of Indian Origin (AAPI) and has served as Scientific Advisor to AAPI for the past five years. AAPI is the second largest physician organization in the US second only to American Medical Association, and the largest ethnic medical organization in the country.

A veteran of the United States Navy Medical Corps, Dr. Chalil is also board certified in healthcare management, and has been awarded Fellowship by the American College of Healthcare Executives, an international professional society of more than 40,000 healthcare executives who lead hospitals, healthcare systems and other healthcare organizations.

Dr. Chalil is an expert in US Healthcare policy and a strong advocate for patient centered care, and has also served as an advisor to various national political campaigns on healthcare issues. Dr. Chalil completed his higher studies in University of Medicine and Dentistry of New Jersey, Davenport University and JJM Medical College. He has been a Visiting Professor at various Universities and serves on various company Boards.

Dr. Chalil holds three US Patents, and his research includes Clinical Trial Management in Cystic Fibrosis, Multiple Myeloma, and publications in American Journal of Respiratory and Critical Care Medicine. He was the recipient of the 2013 Outstanding 50 Asian Americans in Business Award. He is a visiting Professor at various universities and board member of various companies, and the American Association of Cardiologists of Indian Origin (AACIO) honored Dr. Chalil for his achievements in the field of Cardiology in 2013. Dr. Chalil is also the honored recipient of the prestigious 2015 AAPI Presidential Award.

Julian T. Ross, CEO of OxySure said, "We are forward-structuring our Strategic Advisory Board to strengthen our collective expertise in healthcare marketing, sales and business development. Adding Dr. Chalil to our Strategic Advisory Board catapults us significantly forward towards this goal. His depth and breadth of experience in these fields will enable OxySure to take greater advantage of the opportunities that lie ahead."

Dr. Chalil said, "I am honored to join the OxySure Strategic Advisory Board. I look forward to working with the OxySure teams to unlock the significant opportunities I see for OxySure in emergency care and respiratory care, worldwide."

About OxySure Systems, Inc.

OxySure Systems, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from two dry, inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. *In addition to oxygen products for public/lay responder usage, OxySure also markets emergency medical solutions including AEDs, Bleeding Control solutions, resuscitation products and pulse oximetry products.* www.OxySure.com

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts, including, without limitation, statements that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development, may be deemed to be forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. These statements are subject to risks and uncertainties. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Except as may be required under applicable law, we assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of OxySure Systems, Inc. can be found in the filings of OxySure Systems, Inc. with the U.S. Securities and Exchange Commission.

OxySure Contacts:

Renmark Financial Communications, Inc.

Bettina Filippone: bfilippone@renmarkfinancial.com

Tel.: (416) 644-2020 or (514) 939-3989

www.renmarkfinancial.com/

Redchip Companies, Inc.

Jon Cunningham: jon@redchip.com

800-733-2447, ext. 107 | www.redchip.com/

OxySure® Systems, Inc. (OTCQB: OXYS)

10880 John W. Elliot Drive, Suite, 600 / Frisco, TX 75033 / Phone (972) 294-6450 / Fax (972) 294-6501

www.OxySure.com / info@OxySure.com